DIAGNOSTIC METHODS FOR aMCI:
MODELLING FEASIBILITY AND COSTEFFECTIVENESS
V.S. Thomas1, P. Anderson2
1Medical & Scientific Affairs, Roche Professional
Diagnostics, Roche Diagnostics, Rotkreuz, Switzerland,
2Centre for Health Economics, Swansea University,
Swansea, UK
Background: Given long-running concerns over the cost impact and relatively limited clinical effectiveness of
currently marketed therapies for Alzheimer’s disease (AD),novel therapeutics currently in development will likely face considerable scrutiny regarding their relative clinical
benefits, cost effectiveness, as well as reimbursementchallenges, funding issues and likely challenges to use in clinical practice. As a consequence, there is great interest in
the development of diagnostic tools to identify the patients most likely to benefit from treatment to accompany the potential therapeutics. The prodromal stage of AD, which
substantially overlaps with amnestic Mild CognitiveImpairment (aMCI), is of notable interest in the development of AD therapeutics and diagnostics because of the potential
clinical and cost benefits to intervening earlier in the disease progression pathway.
Methods: Our objective is to identify the added value of a diagnostic test that selects patients for targeted therapy. An economic model based evaluation was undertaken, using
established methods, reflecting local treatment practice and comparators. The model has a lifetime perspective and enables the consideration of payer and societal costs. The
model uses economic and outcomes patient level data and published disease progression data on cognition and functional capacities.
Results: The disease progression, patient and service outcomes and treatment pathways that are changed through using a companion diagnostic will be presented.
Conclusion: In our example, using economic modelling and taking a population based approach to identifying the best approach to targeted treatment is a useful approach to
understanding the benefits of companion diagnostics and stratified medicines.
|
||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||
